Jaguar Animal Health (NASDAQ:JAGX) Releases Earnings Results, Beats Estimates By $36.45 EPS

Jaguar Animal Health (NASDAQ:JAGX) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($15.70) EPS for the quarter, beating the consensus estimate of ($52.15) by $36.45, Zacks reports.

Jaguar Animal Health Stock Performance

Shares of JAGX stock traded down $0.03 during midday trading on Wednesday, reaching $0.95. 178,216 shares of the company were exchanged, compared to its average volume of 107,070. The company’s 50 day moving average price is $1.83 and its two-hundred day moving average price is $9.51. The company has a market cap of $567,600.00, a P/E ratio of -0.00 and a beta of -0.06. Jaguar Animal Health has a 12 month low of $0.72 and a 12 month high of $85.40.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on JAGX shares. Wall Street Zen upgraded shares of Jaguar Animal Health from a “sell” rating to a “hold” rating in a report on Saturday, May 23rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jaguar Animal Health in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Jaguar Animal Health presently has a consensus rating of “Sell”.

Jaguar Animal Health Company Profile

Jaguar Animal Health, Inc is a biopharmaceutical company focused on the development and commercialization of novel therapeutics for the gastrointestinal health of food-producing animals, with an emphasis on swine and poultry. The company’s research and development efforts target common enteric disorders such as post-weaning diarrhea in pigs and clostridial overgrowth in broiler chickens, aiming to provide effective alternatives to traditional antibiotic treatments.

Jaguar Animal Health was formed in early 2019 through the acquisition of the animal health business of Aratana Therapeutics by Actinium Animal Health, followed by a corporate rebranding.